Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Equity Ratio (2020 - 2023)

Cullinan Therapeutics (CGEM) has 4 years of Equity Ratio data on record, last reported at 0.95 in Q3 2023.

  • For Q3 2023, Equity Ratio changed 0.2% year-over-year to 0.95; the TTM value through Sep 2023 reached 0.95, changed 0.2%, while the annual FY2022 figure was 0.95, 2.0% down from the prior year.
  • Equity Ratio reached 0.95 in Q3 2023 per CGEM's latest filing, down from 0.96 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.99 in Q2 2021 and bottomed at 0.91 in Q2 2022.
  • Average Equity Ratio over 4 years is 0.96, with a median of 0.96 recorded in 2022.
  • Peak YoY movement for Equity Ratio: fell 8.24% in 2022, then grew 5.62% in 2023.
  • A 4-year view of Equity Ratio shows it stood at 0.93 in 2020, then rose by 4.29% to 0.97 in 2021, then decreased by 2.0% to 0.95 in 2022, then decreased by 0.61% to 0.95 in 2023.
  • Per Business Quant database, its latest 3 readings for Equity Ratio were 0.95 in Q3 2023, 0.96 in Q2 2023, and 0.94 in Q1 2023.